Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of California, San Francisco
With
E-DA Hospital
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects that are scheduled for bariatric surgery.
Subjects that are able and willing to donate surplus intestinal tissue.
Subjects with solute carrier organic anion transporter \*1 (SLCO1B1) and breast cancer resistant protein (BCRP) 421CC genotypes.
White/Caucasian/European and Asian/East Asian heritage individuals, male or female, 18 years of age or older.
BMI between 30-55 kg/m2
Be able to read, speak, and understand English(UCSF) and Chinese(Taiwan).
Subjects capable of providing informed consent and completing the requirements of the study.
You may not be if
Subjects with active liver and kidney problems, severe cardiovascular diseases, type I diabetes, advanced pulmonary disease, and cancers.
Subjects on chronic prescription or over the counter medication that have previously been reported to exhibit drug-drug interactions with rosuvastatin and cannot be stopped two weeks prior to and during the study, including gemfibrozil, cyclosporine, atazanavir, lopinavir and ritonavir.
Subjects incapable of multiple blood draws (HCT \< 30mg/dL).
Subjects with a history of rhabdomyolysis.
Subjects with a history of drug-related myalgias.
Subjects with a history or diagnosis of hemorrhagic tendencies or blood dyscrasias.
Subjects with a history of GI bleed or peptic ulcer disease.
Subjects with a recent history of trauma.
Subjects who smoke tobacco or have ongoing alcohol or illegal drug use.
Subjects who are pregnant, lactating, or trying to conceive during the study period.
Subjects allergic to rosuvastatin or any known component of the medications.
